1700029G01Rik Inhibitors encompass a diverse array of compounds that can interact with and modulate the activity of the protein encoded by the gene 1700029G01Rik, known as Sh3d21. These inhibitors demonstrate a range of chemical structures and properties, each strategically designed to influence the activity of Sh3d21 in specific ways. Their mechanisms of action can include direct binding to the protein, altering its structural conformation, affecting its enzymatic activity, or disrupting its interaction with other cellular molecules. The diversity of these mechanisms reflects the complexity of protein functions and the intricacy of cellular biochemical networks.
The development and study of these inhibitors involve substantial scientific efforts, integrating aspects of molecular biology, chemistry, and computational biology. Researchers use advanced computational methods to model the protein structure and predict potential binding sites for inhibitors. The synthesis of these molecules employs sophisticated techniques in synthetic chemistry, aiming to create compounds ranging from small, targeted molecules to larger, more complex structures. Experimental validation, including biochemical assays and cellular studies, is crucial to determine the actual impact of these inhibitors on the protein's function. This research not only contributes to understanding the specific protein but also enhances broader knowledge in cellular biochemistry and molecular biology.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Kinase inhibitor, can disrupt phosphorylation processes potentially involving 1700029G01Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, can impact the PI3K/Akt signaling pathway, potentially affecting 1700029G01Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, can influence cell growth and autophagy, potentially impacting 1700029G01Rik. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor, can modify gene expression and chromatin structure, potentially affecting 1700029G01Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MAPK/ERK pathway inhibitor, can alter cell signaling processes involving 1700029G01Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor, can disrupt stress response and inflammation, potentially linked to 1700029G01Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
JNK inhibitor, can alter stress response and apoptosis, potentially involving 1700029G01Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor, can disrupt various signaling pathways potentially linked to 1700029G01Rik. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, can influence protein degradation, potentially impacting 1700029G01Rik. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Calcium channel blocker, can alter calcium signaling, potentially affecting 1700029G01Rik. |